Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

MONSTAR-SCREEN-3 preliminary cohort detected baseline ctDNA across 15 solid-tumor types

An ASCO 2025 preliminary report from MONSTAR-SCREEN-3, with 114 patients across 15 cancer types as of December 2024, found baseline ctDNA in 41 of 41 tested patients and postoperative month-1 MRD positivity in 10 of 28, including colorectal, gastric, head and neck, renal cell, esophageal, and pancreatic cancers.

Journal of Clinical Oncology